Agile Therapeutics: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Agile Therapeutics (OTC:AGRX) reported Q4 earnings with a significant miss on estimated earnings by -59.0%, posting an EPS of $-1.46 against an estimate of $-0.92. Revenue also declined by $381 thousand from the same period last year. Despite beating EPS estimates in the previous quarter, the share price dropped by 2.0% the following day.
March 28, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Agile Therapeutics reported a significant miss in Q4 earnings with an EPS of $-1.46 against estimates of $-0.92 and a revenue decline from the previous year.
The significant miss in both earnings and revenue compared to estimates and the previous year's performance is likely to negatively impact investor sentiment and the stock price in the short term. Historical data shows a previous earnings beat was followed by a share price drop, indicating market sensitivity to the company's financial performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100